Dexamethasone sodium phosphate SR is under clinical development by Taiwan Liposome and currently in Phase III for Osteoarthritis Pain. According to GlobalData, Phase III drugs for Osteoarthritis Pain have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Dexamethasone sodium phosphate SR’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Dexamethasone sodium phosphate SR overview
TLC-599 is under development for the treatment of osteoarthritis knee, hip, shoulder and small joint pain. The drug candidate is administered via intraarticular injection. It is a sustained release formulation of dexamethasone sodium phosphate. It targets glucocorticoid receptor (GR). The drug candidate is a corticosteroid based on BioSeizer lipid based technology.
Taiwan Liposome overview
Taiwan Liposome (TLC) is a clinical-stage pharmaceutical company, which develops and commercializes novel nanomedicines based on drug delivery technology platform. Its pipeline products include TLC599 which treats osteoarthritis; TLC590 for local anesthetic; TLC399 treats macular edema; TLC178 for adult advanced malignancies, soft tissue sarcoma and pediatric rhabdomyosarcoma; Ampholipad which treats systemic fungal infections; ISPM19 for coronavirus disease. The company also develops BioSeizer lipid formulation technology and NanoX active drug loading technology. Its products find applications in the therapeutic areas of pain management, oncology, ophthalmology and infectous disease. The company has operations in Taiwan, the US and the Netherlands. TLC is headquartered in Taipei, Taiwan.
For a complete picture of Dexamethasone sodium phosphate SR’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
